Cancer Control and Population Sciences Program ABSTRACT The mission of the Cancer Control and Population Sciences (CCPS) Program is to advance the science and application of cancer etiology, prevention, and outcomes research. The goal is to reduce the burden of cancer and its sequelae across all segments of the population through collaborative, multidisciplinary efforts. To achieve this goal, the Program has three themes: 1) To discover host and environmental factors contributing to cancer; 2) To identify factors to reduce health-related morbidity and mortality from cancer treatment; and 3) To develop, implement and evaluate interventions to reduce cancer-related morbidity/mortality and improve quality of life (QOL). Within each of these themes, research is on-going to reduce health disparities within our catchment area. As importantly, each theme encompasses strong education components ranging from K-12 programs in the community to healthcare provider and caregiver training for better communication and care for cancer survivors. Targeted recruits with national prominence add both depth and breadth to the Program and include Drs. Seewaldt, Chlebowski, Gray, Kittles, and Yee. The CCPS Program is particularly invested in the following key areas: building a robust portfolio of research in cancer etiology and biomarker development; strengthening the focus on understanding risk factors for treatment-related complications and developing tailored interventions to reduce morbidity in cancer survivors; recognizing causes of disparities in outcome unique to disease type and developing tailored interventions to systematically mitigate the disparities; and continuing to build upon the strong portfolio of research in psychosocial outcomes and tailored interventions to improve QOL. Sponsored activities include monthly work in progress meetings, monthly seminars, an annual retreat, and annual pilot funding. Membership: 23 Program Members representing 4 basic and clinical departments Publications: 410 total. 34.6% intra-programmatic; 20.2% inter-programmatic; 58.0% inter-institutional Funding: $7,770,700 peer-reviewed; $5,788,708 of which is NCI funding

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA033572-38
Application #
10059210
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Roberson, Sonya
Project Start
1997-08-01
Project End
2022-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
38
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Beckman Research Institute/City of Hope
Department
Type
DUNS #
027176833
City
Duarte
State
CA
Country
United States
Zip Code
91010
Gong, Jun; Salgia, Ravi (2018) Managing Patients With Relapsed Small-Cell Lung Cancer. J Oncol Pract 14:359-366
Chen, Robert W; Palmer, Joycelynne M; Tomassetti, Sarah et al. (2018) Multi-center phase II trial of bortezomib and rituximab maintenance combination therapy in patients with mantle cell lymphoma after consolidative autologous stem cell transplantation. J Hematol Oncol 11:87
Romsdahl, Jillian; Blachowicz, Adriana; Chiang, Abby J et al. (2018) Characterization of Aspergillus niger Isolated from the International Space Station. mSystems 3:
Sen, Subha; He, Zhiheng; Ghosh, Shubhamoy et al. (2018) PRMT1 Plays a Critical Role in Th17 Differentiation by Regulating Reciprocal Recruitment of STAT3 and STAT5. J Immunol 201:440-450
Lueschow, Shiloh R; Stumphy, Jessica; Gong, Huiyu et al. (2018) Loss of murine Paneth cell function alters the immature intestinal microbiome and mimics changes seen in neonatal necrotizing enterocolitis. PLoS One 13:e0204967
Gu, Long; Lingeman, Robert; Yakushijin, Fumiko et al. (2018) The Anticancer Activity of a First-in-class Small-molecule Targeting PCNA. Clin Cancer Res 24:6053-6065
Zhao, Xingli; Zhang, Zhuoran; Moreira, Dayson et al. (2018) B Cell Lymphoma Immunotherapy Using TLR9-Targeted Oligonucleotide STAT3 Inhibitors. Mol Ther 26:695-707
Weitzel, Jeffrey N; Chao, Elizabeth C; Nehoray, Bita et al. (2018) Somatic TP53 variants frequently confound germ-line testing results. Genet Med 20:809-816
Ghose, Jayeeta; Viola, Domenico; Terrazas, Cesar et al. (2018) Daratumumab induces CD38 internalization and impairs myeloma cell adhesion. Oncoimmunology 7:e1486948
Aslamy, Arianne; Oh, Eunjin; Olson, Erika M et al. (2018) Doc2b Protects ?-Cells Against Inflammatory Damage and Enhances Function. Diabetes 67:1332-1344

Showing the most recent 10 out of 1396 publications